Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post COVID Syndrome’

Neobiosis, a UF Accelerate resident client, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of Post COVID Syndrome (AKA “Long Haul COVID Syndrome”).

“This is an important milestone for Neobiosis and we are excited to be advancing ViXome, a refined product extracted from thoroughly screened and sterile amniotic fluid obtained at the time of c-section of at-term pregnancies, into clinical development,” said Ian A. White, Ph.D., CEO and CSO of Neobiosis. “We are eager to confirm our preclinical data in the clinic and expect to begin enrolling patients in Phase 1 during the second quarter of 2024.”

Learn more about Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post COVID Syndrome’